USPTO serial 90858111
PROTEOVANT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 1, 2023
- Examiner
- SINGH, TEJBIR
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PROTEOVANT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Allison Strickland Ricketts
Allison Strickland Ricketts FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND STREET, 17TH FLOORNEW YORK, NY 10036UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for human use comprising small molecules for degrading disease-causing cellular proteins for prevention and treatment of oncological, allergy and immunological, neurological, cardiac, dermatological, endocrinological, gastroenterological, hematological, infectious, genetic, nephrological, gynecological, ophthalmological, orthopedic, otorhinolaryngological, podiatric, psychiatric, pulmonological, respiratory, rheumatological, and urological diseases and disorders; biologic preparations for medical and therapeutic purposes comprising small molecules for degrading disease-causing cellular proteins for prevention and treatment of oncological, allergy and immunological, neurological, cardiac, dermatological, endocrinological, gastroenterological, hematological, infectious, genetic, nephrological, gynecological, ophthalmological, orthopedic, otorhinolaryngological, podiatric, psychiatric, pulmonological, respiratory, rheumatological, and urological diseases and disorders; pharmaceutical and biological preparations for treatment and prevention of cancer and for the treatment and prevention of auto-immune diseases and disorders and central nervous system and neurological diseases and disorders | ACTIVE | — |
| 042 | Pharmaceutical product development for new small molecules aimed at degrading disease-causing cellular proteins for treatment in the field of oncology; scientific and technological services, namely, medical research, scientific research and analysis in the field of pharmaceuticals and biomedicine; pharmaceutical and biomedical research services; research in the field of pharmaceutical and biologic therapeutic preparations; pharmaceutical research and development; providing scientific research information in the field of pharmaceuticals and biomedicine | ACTIVE | — |
| 044 | Providing health and medical information; providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Roivant Sciences GmbH
- Other trademarks owned by Roivant Sciences GmbH
- Other trademarks owned by Roivant Sciences GmbH
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PROTEOVANT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 1, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 1, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 16, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 16, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 26, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 12, 2023 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Apr 7, 2023 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Apr 3, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 17, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 17, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 17, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 28, 2023 | RDX3 | NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED | — |
| Feb 28, 2023 | RDX1 | ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED | — |
| Feb 28, 2023 | RRDX | ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED | — |
| Feb 15, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 14, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2023 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Nov 29, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 29, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 29, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 28, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 27, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 27, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 5, 2021 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Oct 4, 2021 | ALIE | ASSIGNED TO LIE | — |
| Sep 27, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 4, 2021 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Aug 3, 2021 | NWAP | NEW APPLICATION ENTERED | — |